Wed October 12th, 2016
Stem Cell Assays | Research on Stem Cells
Stem Cell Assays growth can be attributed to the high prevalence of chronic diseases, increasing investment in research related activities, and technological advancements. However, stringent regulatory policies and high cost of stem cell based therapies are major factors restraining the growth of Stem Cell Assays. Get FREE Sample PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=47610330 On the basis of type of assay, the Stem Cell Assays is segmented into viability/cytotoxicity, isolation & purification, cell identification, proliferation, differentiation, function and apoptosis. The viability/cytotoxicity segment is expected to be the largest and fastest-growing segment of the global market in 2016.; whereas, the isolation & purification segment is expected to grow at the highest CAGR during the forecast period. The major players in the stem cell assay market are include GE Healthcare (U.K.), Promega Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (U.S.), Cell Biolabs, Inc. (U.S.), Hemogenix Inc. (U.S.), STEMCELL Technologies Inc. (CA), Bio-Rad Laboratories, Inc. (U.S.), Bio-Techne Corporation (U.S.), and Cellular Dynamics International, Inc. (U.S.).